PD-1 Inhibitors + Irinotecan + Capecitabine tablets
Phase 3UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Esophageal Squamous Cell Carcinoma Abdominal Stage 0
Conditions
Esophageal Squamous Cell Carcinoma Abdominal Stage 0
Trial Timeline
Feb 17, 2023 → Feb 17, 2026
NCT ID
NCT05737563About PD-1 Inhibitors + Irinotecan + Capecitabine tablets
PD-1 Inhibitors + Irinotecan + Capecitabine tablets is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Esophageal Squamous Cell Carcinoma Abdominal Stage 0. The current trial status is unknown. This product is registered under clinical trial identifier NCT05737563. Target conditions include Esophageal Squamous Cell Carcinoma Abdominal Stage 0.
What happened to similar drugs?
19 of 20 similar drugs in Esophageal Squamous Cell Carcinoma Abdominal Stage 0 were approved
Approved (19) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05737563 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Esophageal Squamous Cell Carcinoma Abdominal Stage 0